Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Abstract Representative in vitro model systems that accurately model response to therapy and allow the identification of new targets are important for improving our treatment of prostate cancer. Here we describe molecular characterization and drug testing in a panel of 20 prostate cancer cell lines....
Guardado en:
Autores principales: | Rebecca Smith, Moqing Liu, Tiera Liby, Nora Bayani, Elmar Bucher, Kami Chiotti, Daniel Derrick, Anne Chauchereau, Laura Heiser, Joshi Alumkal, Heidi Feiler, Peter Carroll, James E. Korkola |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/708df8dc657045d19f9756d95d497a15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: Yundong He, et al.
Publicado: (2021) -
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
por: Qiuhui Li, et al.
Publicado: (2018) -
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Keliang Wang, et al.
Publicado: (2020) -
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Ayşe Demirci, et al.
Publicado: (2021) -
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review
por: Min Deng, et al.
Publicado: (2021)